Actavis settles sublingual tablet patent spat with Orexo; FDA releases guidance on injectable packaging;

> Actavis Laboratories ($ACT) reached a settlement agreement on patent infringement litigation filed by Orexo. The suit was filed after Actavis filed for a generic version of Orexo's Abstral sublingual tablet for cancer pain. Under the agreement, Actavis can enter the market in June 2018. More

> The FDA released a draft guidance about injectable meds entitled "Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use." More

> Ocular Therapeutix ($OCUL) said its intracanalicular depot for allergic conjunctivitis met its primary endpoint in a clinical trial. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.